Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2005 Aug;20(4):591-7.
doi: 10.3346/jkms.2005.20.4.591.

Comparison of clinical efficacy of Newfactan versus Surfacten for the treatment of respiratory distress syndrome in the newborn infants

Chang Won Choi  1 , Jong Hee Hwang, Eun Jung Yoo, Kyung Ah Kim, Sun Young Koh, Yeon Kyung Lee, Jae Won Shim, Eun Kyung Lee, Wook Chang, Sung Shin Kim, Yun Sil Chang, Won Soon Park, Son Moon Shin
Affiliations
Clinical Trial

Comparison of clinical efficacy of Newfactan versus Surfacten for the treatment of respiratory distress syndrome in the newborn infants

Chang Won Choi et al. J Korean Med Sci. 2005 Aug.

Abstract

Newfactan is a domestically developed, bovine lung-derived, semi-synthetic surfactant. The aim of this study was to compare the clinical efficacy of Newfactan with that of Surfacten in the treatment of respiratory distress syndrome (RDS). Newfactan or Surfacten was randomly allocated to 492 newborn infants who were diagnosed as RDS and required surfactant instillation in four participating hospitals. The comparisons were made individually in two subsets of infants by birth weight (<1,500 g group [n=253] and > or =1,500 g group [n=239]). Short-term responses to surfactant and acute complications, such as the total doses of surfactant instilled, response type, extubation rate, ventilator settings, changes in respiratory parameters, air leak, patent ductus arteriosus, pulmonary hemorrhage, and intraventricular hemorrhage, and mortality during the 96 hr after surfactant instillation were measured. Long-term outcome and complications, such as total duration of intubation, bronchopulmonary dysplasia and periventricular leukomalacia, and ultimate mortality were measured. There were no significant differences in demographic and perinatal variables, shortterm responses to surfactant and acute complications, and long-term outcome and complications between Newfactan and Surfacten in both birth weight groups. We concluded that Newfactan was comparable to Surfacten in the clinical efficacy in the treatment of RDS in both birth weight groups.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
The distribution of total subject infants according to the participating hospitals (A) and the distribution of the infants in <1,500 g group according to birth weight (B). The figures designate the number of infants.
Fig. 2
Fig. 2
The time courses of FiO2 and mean airway pressure (MAP) over the 96 hr after surfactant instillation between Newfactan® group and Surfacten® group in <1,500 g group and ≥1,500 g group. (A) FiO2 in <1,500 g group; (B) Mean airway pressure in <1,500 g group; (C) FiO2 in ≥1,500 g group; (D) mean airway pressure in ≥1,500 g group. There were no significant differences in the time courses of FiO2 and mean airway pressure in both <1,500 g group and ≥1,500 g group.
Fig. 3
Fig. 3
The time courses of arterial-alveolar oxygen ratio (a/APO2) and ventilatory index (VI) over the 96 hr after surfactant instillation between Newfactan® group and Surfacten® group in <1,500 g group and ≥1,500 g group. (A) a/APO2 in <1,500 g group; (B) VI in <1,500 g group; (C) a/APO2 in ≥1,500 g group; (D) VI in ≥1,500 g group. There were no significant differences in the time courses of a/APO2 and VI in both <1,500 g group and ≥1,500 g group.
See this image and copyright information in PMC

References

    1. Rodriguez RJ. Management of respiratory distress syndrome: an update. Respir Care. 2003;48:279–286. - PubMed
    1. Namgung R, Lee C, Suh JS, Park KI, Han DG. Exogenous surfactant replacement therapy of hyaline membrane disease in premature infants. Yonsei Med J. 1989;30:355–366. - PubMed
    1. Bae CW, Kwon YD, Ko SJ, Kim KS, Kim HM, Park WS, Byun SH, Son CS, Ahn HS, Lee SG, Chang YP, Chung YJ. Surfactant replacement therapy in neonates with respiratory distress syndrome: a collective evaluation of trials from 16 hospitals. J Korean Pediatr Soc. 1993;36:244–265.
    1. Bae CW. The second ChoongWae surfactant symposium program book. Seoul: Choong-Wae Pharma Corporation; 2004. Surfactant therapy: history and future; pp. 15–24.
    1. Bae CW, Choi YM, Lee SC, Kang JH, Kim KL, Hahm KS. Comparison of in vitro surface physical properties of four artificial exogeneous pulmonary surfactant preparations. J Korean Pediatr Soc. 1999;42:1215–1223.

Publication types

Substances